BioSpace News Archive

Researchers from Yale School of Public Health find that genetic profiling for cancer tumors is cost-effective for high- and medium-risk patients with breast cancer, but is unlikely to make a meaningful impact on treatment for low-risk patients.

Baylis Medical announced today the Canadian launch and first clinical use of its ExpanSure™ Transseptal Dilation System.

No financial details of the agreement were released.

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) has published encouraging results from a clinical trial of OTL-300, an autologous ex vivo lentiviral gene therapy program being studied in individuals with transfusion-dependent beta-thalassemia

Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDOTM test.

Leading managed care plans in Tennessee have adopted CAQH ProViewⓇ to increase the accuracy of provider data in the state.

--Collaboration will leverage CAMP4’s Gene Circuitry Platform™ to rapidly identify novel signaling pathway targets for potential RNAi intervention

Company Founded with Mission to Give Stroke Patients the Best Chance for Optimal Recovery

The Paragonix SherpaPak™ CTS is the only FDA cleared and CE marked system for donor organ heart transport and storage.

The round was co-led by existing investors KKR and Viking Global Investors.